natgillin/translations-raw huggingface dataset:
Therefore, caution should be exercised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily (see sections 4.8 and 5.2).
Dakle, oprez je potreban kada se liječe bolesnici u dobi ≥ 65 godina dozama višim od 10 mg vortioksetina jednom dnevno (vidjeti dijelove 4.8 i 5.2).
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance > 80 ml/min).
Stoga je nužan oprez pri istodobnoj primjeni pemetrekseda i viših doza NSAIL-a ili acetilsalicilatne kiseline u bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina ≥ 80 ml/min).
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance > 80 ml/min).
Stoga je nužan oprez pri istodobnoj primjeni pemetrekseda i viših doza NSAIL-a ili aspirina u bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina ≥ 80 ml/min).
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Stoga je nužan oprez pri istodobnoj primjeni pemetrekseda i viših doza NSAIL-a ili acetilsalicilatne kiseline u bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina ≥ 80 ml/min).
Therefore, caution should be observed when co-administering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).
Stoga je potreban oprez kad se istodobno primjenjuju Dynastat i lijekovi koje pretežno metabolizira CYP2D6 i koji imaju uske terapijske granice (npr. flekainid, propafenon, metoprolol).
Therefore, caution should be recommended when driving a car or operating machinery.
Stoga se preporučuje oprez pri upravljanju vozilima ili radu na strojevima.
Therefore, caution should be recommended when driving a car or operating machines.
Stoga se preporučuje oprez pri upravljanju vozilima ili radu sa strojevima.
Therefore, caution should be taken if these drugs are co-administered with olaparib and patients should be closely monitored.
Stoga je pri istodobnoj primjeni tih lijekova s olaparibom potreban oprez i pažljiv nadzor bolesnika.
Therefore, caution should be used during handling and preparation of Bortezomib Accord.
Stoga je potreban oprez tijekom rukovanja i pripreme Bortezomib Accorda.
Therefore, caution should be used during handling and preparation of Bortezomib SUN.
Stoga je potreban oprez tijekom rukovanja i pripreme Bortezomib SUN-a.
Therefore, caution should be used during handling and preparation of VELCADE.
Stoga je potreban oprez tijekom rukovanja i pripreme VELCADEa.
Therefore, caution should be used when co-administration of eltrombopag with LPV/RTV takes place.
Stoga je potreban oprez prilikom istodobne primjene eltrombopaga i LPV/RTV.
Therefore, ceritinib should be used with caution in patients who have or may develop prolongation of the QT interval, including those patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other medicinal products that may lead to QT prolongation such as astemizole, domperidone, droperidol, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin.
Stoga je ceritinib potrebno primjenjivati s oprezom u bolesnika koji imaju ili u kojih može doći do produljenja QT intervala, uključujući one bolesnike koji uzimaju antiaritmike kao što su antiaritmici klase I (npr. kinidin, prokainamid, dizopiramid) ili klase III (npr. amiodaron, sotalol, dofetilid, ibutilid) ili druge lijekove koji mogu dovesti do produljenja QT intervala kao što su astemizol, domperidon, droperidol, klorokin, halofantrin, klaritromicin, haloperidol, metadon, cisaprid i moksifloksacin.
Therefore, Cimzia is not recommended during pregnancy.
Stoga ne preporučuje se primjenjivati Cimziju u trudnoći.
Therefore, clinical consequences of ECT concomitant treatment with Thymanax are considered to be unlikely.
Stoga, nije vjerojatna pojava kliničkih posljedica kod istovremenog EKT liječenja i liječenja lijekom Thymanax.
Therefore, clinical consequences of ECT concomitant treatment with Valdoxan are considered to be unlikely.
Stoga, nije vjerojatna pojava kliničkih posljedica kod istovremenog EKT liječenja i liječenja lijekom Valdoxan.
Therefore, clinical medicinal product interactions are unlikely to occur as a result of ponatinib- mediated inhibition of substrates for these transporters.
Stoga nisu vjerojatne kliničke interakcije lijekova koje će se javljati kao rezultat inhibicije supstrata ovih transportera ponatinibom.
Therefore, clinical monitoring
Stoga se preporučuje kliničko praćenje, s
Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see sections 4.4 and 5.2).
Zato je u tih pacijenata nužno pažljivo pratiti klinički odgovor na liječenje i funkciju bubrega (vidjeti dijelove 4.4 i 5.2).
Therefore, clinically relevant interactions with other drugs through competition for protein binding sites are considered unlikely.
Stoga se klinički značajne interakcije s drugim lijekovima zbog kompetitivnog vezanja za proteine smatraju malo vjerojatne.
Therefore, clinically relevant interactions would not be expected with other P- glycoprotein/CYP3A4 inhibitors.
Stoga se ne očekuju klinički značajne interakcije s drugim inhibitorima P-glikoproteina/CYP3A4.
Therefore, clinically significant pharmacokinetic drug-drug interactions in metabolism related to these isoenzymes are unlikely.
Stoga klinički značajne farmakokinetičke interakcije lijekova koji se metaboloziraju putem tih izoenzima nisu vjerojatne.
Therefore, close clinical surveillance (looking for signs of bleeding or anaemia) is required when dabigatran is co-administered with verapamil.
Stoga je potreban poman klinički nadzor (praćenje znakova krvarenja ili anemije) kada se dabigatran primjenjuje istovremeno s verapamilom.
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic medicinal products that are eliminated by renal tubular secretion are co-administered.
Stoga, kad se istodobno primjenjuju kationski lijekovi koji se eliminiraju sekrecijom u bubrežnim tubulima, treba razmotriti strogo praćenje glikemijske kontrole, prilagodbu doze unutar okvira preporučenog doziranja i promjena u liječenju dijabetesa.
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic medicinal products that are eliminated by renal tubular secretion are co-administered.
Stoga, kod istodobne primjene kationskih lijekova koji se izlučuju bubrežnim tubulima, treba razmotriti pomno praćenje kontrole glikemije, prilagodbu doze u okviru preporučenog doziranja i promjene u režimu liječenja dijabetesa.
Therefore, close monitoring of growth in children and adolescents under imatinib treatment is recommended (see section 4.8).
Stoga se preporučuje pažljivo praćenje rasta kod djece i adolescenata koji se liječe imatinibom (vidjeti dio 4.8).
Therefore, close monitoring of growth in children under imatinib treatment is recommended (see section 4.8).
Stoga se preporučuje pažljivo praćenje rasta djece koja se liječe imatinibom (vidjeti dio 4.8).
Therefore, close monitoring of growth in children under imatinib treatment is recommended (see section 4.8).
Stoga se preporučuje pažljivo praćenje rasta kod djece koja se liječe imatinibom (vidjeti dio 4.8).
Therefore, close monitoring of growth in paediatric patients under treatment with imatinib is recommended (see section 4.8).
Stoga se preporučuje pažljivo praćenje rasta u pedijatrijskih bolesnika koji se liječe imatinibom (vidjeti dio 4.8).
Therefore, co-administration of
Kombinacija avanafila i lijeka
Therefore, co-administration of
Stoga je istodobna primjena
Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, cidofovir) or MRP2 (e.g. ritonavir) may increase the systemic exposure of LBQ657 or valsartan.
Stoga istodobna primjena Entresta s inhibitorima OATP1B1, OATP1B3, OAT3 (npr. rifampicinom, ciklosporinom), OAT1 (npr. tenofovirom, cidofovirom) ili MRP2 (npr. ritonavirom) može povećati sistemsku izloženost LBQ657 ili valsartanu.
Therefore, co-administration of ISENTRESS with aluminium and/or magnesium containing antacids is not recommended.
Iz toga se razloga istodobna primjena lijeka ISENTRESS s antacidima koji sadrže aluminij i/ili magnezij ne preporučuje.
Therefore, co-administration of lumacaftor/ivacaftor is not recommended with strong CYP3A inducers.
Stoga se ne preporučuje istodobna primjena lumakaftora/ivakaftora i jakih induktora CYP3A.
Therefore, co-administration of Neparvis with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, cidofovir) or MRP2 (e.g. ritonavir) may increase the systemic exposure of LBQ657 or valsartan.
Stoga istodobna primjena Neparvisa s inhibitorima OATP1B1, OATP1B3, OAT3 (npr. rifampicinom, ciklosporinom), OAT1 (npr. tenofovirom, cidofovirom) ili MRP2 (npr. ritonavirom) može povećati sistemsku izloženost LBQ657 ili valsartanu.
Therefore, co-administration of ONIVYDE with inducers of CYP3A4 may reduce systemic exposure of ONIVYDE.
Stoga, istodobna primjena lijeka ONIVYDE s induktorima CYP3A4 može smanjiti sustavnu izloženost lijeku ONIVYDE.
Therefore, co-administration of ONIVYDE with other inhibitors of CYP3A4 (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) may increase systemic exposure of ONIVYDE.
Stoga, istodobna primjena lijeka ONIVYDE s drugim inhibitorima CYP3A4 (npr. sok od grejpa, klaritromicin, indinavir, itrakonazol, lopinavir, nefazodon, nelfinavir, ritonavir, sakvinavir, telaprevir, vorikonazol) može povećati sustavnu izloženost lijeku ONIVYDE.
Therefore, co-administration of Senshio with strong enzyme inducers like carbamazepine, phenytoin, St John’s wort and rifabutin would be expected to decrease the exposure of ospemifene, which may decrease the clinical effect.
Stoga bi se pri istodobnoj primjeni lijeka Senshio s jakim induktorima enzima poput karbamazepina, fenitoina, gospine trave i rifabutina očekivalo smanjenje izloženosti ospemifenu, što može smanjiti klinički učinak.
Therefore, co-administration of Senshio with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known, or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.
Stoga je istodobnu primjenu Senshia sa snažnim/umjerenim inhibitorima CYP3A4 potrebno izbjegavati u bolesnika za koje se, na temelju genotipizacije ili ranijih podataka u anamnezi/iskustava/ s drugim supstratima CYP2C9, zna ili sumnja da su slabi metabolizatori CYP2C9.
Therefore, co-administration with strong CYP3A inducers (e.g., rifampicin, St. John’s wort [Hypericum perforatum]) is not recommended (see section 4.5).
Stoga se ne preporučuje istodobna primjena s jakim induktorima CYP3A (npr. rifampicinom, gospinom travom [Hypericum perforatum]) (vidjeti dio 4.5).
Therefore, Coagadex should be used during breast- feeding only if clearly indicated.
Stoga se Coagadex smije primjenjivati tijekom dojenja samo ako je jasno indicirano.
Therefore, concomitant administration of CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin, barbiturates or herbal preparations containing St John’s wort/Hypericum perforatum) may reduce efficacy of the treatment and should be avoided (see section 4.5).
Stoga istodobna primjena induktora CYP3A4 (npr. fenitoin, karbamazepin, rifampicin, barbiturati ili biljni pripravci koji sadrže gospinu travu/Hypericum perforatum) može smanjiti djelotvornost liječenja te se treba izbjegavati (vidjeti dio 4.5).
Therefore, concomitant administration of CYP3A4 inducers (such as rifampicin, phenytoin, carbamazepine, phenobarbital, St John’s wort) is likely to result in subtherapeutic levels of telithromycin and loss of effect.
Stoga će istodobna primjena s induktorima CYP3A4 (kao što su rifampicin, fenitoin, karbamazepin, fenobarbital, gospina trava) vjerojatno dovesti do subterapijske razine telitromicina i gubitka učinka.
Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.
Stoga se istodobna primjena jakih induktora CYP3A4 mora izbjegavati osim ako se bolesnike pažljivo ne promatra zbog mogućih znakova i simptoma tromboze.
Therefore, concomitant administration of tolvaptan with potent CYP3A inducers (e.g., rifampicin, rifabutin, rifapentin, phenytoin, carbamazepine, and St. John’s Wort) is to be avoided.
Zato istovremenu primjenu tolvaptana s jakim induktorima CYP3A (npr. rifampicin, rifabutin, rifapentin, fenitoin, karbamazepin i gospina trava) treba izbjegavati.
Therefore, concomitant treatment with agents that have CYP3A4/5 induction potential should be avoided (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John’s wort) (see section 4.4).
Stoga je potrebno izbjegavati istodobno liječenje tvarima koje mogu inducirati CYP3A4/5 [npr. karbamazepin, fenobarbital, fenitoin, rifampicin i gospina trava] (vidjeti dio 4.4).
Therefore, concomitant treatment with other P-gp substrates could lead to enhanced toxicity.
Dakle usporedno liječenje s ostalim P-gp supstratima može uzrokovati pojačanu toksičnost.
Therefore, concomitant use of IMBRUVICA with strong or moderate CYP3A4 inhibitors/inducers should be avoided whenever possible and co-administration should only be considered when the potential benefits clearly outweigh the potential risks.
Stoga se istodobna primjena lijeka IMBRUVICA sa snažnim ili umjerenim CYP3A4 inhibitorima/induktorima mora izbjegavati kada god je moguće, a istodobna primjena može se uzeti u obzir samo kada potencijalna korist jasno nadvladava potencijalne rizike.
Therefore, concomitant use of lumacaftor/ivacaftor with CYP3A substrates may decrease the exposure of these substrates.
Stoga istodobna primjena lumakaftora/ivakaftora sa supstratima CYP3A može smanjiti izloženost tim supstratima.
Therefore, concomitant use of moderate and strong CYP3A inducers (e.g. carbamazepine, rifampicin, phenytoin, and St. John’s Wort) should be avoided.
Stoga treba izbjegavati istodobnu primjenu umjerenih i snažnih induktora CYP3A (npr. karbamazepina, rifampicina, fenitoina i gospine trave).
Therefore, concomitant use of posaconazole and vinca alkaloids should be avoided unless the benefit to the patient outweighs the risk.
Stoga istodobnu primjenu posakonazola i vinka alkaloida treba izbjegavati, osim ako moguća korist za bolesnika nadilazi rizik liječenja.
Therefore, concomitant use of STAYVEER and tacrolimus or sirolimus is not advisable.
Stoga se istodobna primjena STAYVEERA i takrolimusa ili sirolimusa ne preporuča.
Therefore, concurrent therapy with ORENCIA and a TNF-inhibitor is not recommended.
Stoga se ne preporučuje istodobna terapija lijekom ORENCIA i TNF-inhibitorom.
Therefore, constipation should be included in the section 4.8 of the SmPC.
Zbog toga je potrebno uključiti konstipaciju u dio 4.8 SmPC-a.
Therefore, current smokers should be advised to stop smoking, as plasma concentrations of erlotinib in smokers as compared to non-smokers are reduced.
Stoga, pušačima treba savjetovati da prestanu pušiti jer je ustanovljeno da je koncentracija erlotiniba u plazmi pušača manja u usporedbi s koncentracijom erlotiniba u nepušača.
Therefore, cysteamine bitartrate should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.4).
Stoga se cisteamin bitartrat ne smije koristiti tijekom trudnoće, osobito tijekom prvog tromjesečja, osim ako to nije izričito potrebno (vidjeti dio 4.4).
Therefore, darunavir must only be used in combination with a pharmacokinetic enhancer (see section 5.2).
Stoga se darunavir mora primjenjivati samo u kombinaciji s farmakokinetičkim pojačivačem (vidjeti dio 5.2).
Therefore, despite of the limited number of cases, hypertensive crisis should be included in section 4.8 of the SmPC.
Zbog toga je, unatoč ograničenom broju slučajeva, hipertenzivnu krizu potrebno uključiti u dio 4.8 SmPC-a.
Therefore, diarrhoea should be included in section 4.8 of the SmPC.
Zbog toga je potrebno uključiti proljev u dio 4.8 SmPC-a.
Therefore, dizziness should be included in the section 4.8 of the SmPC.
Zbog toga je potrebno uključiti omaglicu u dio 4.8 SmPC-a.
Therefore, do not take Comtan and iron supplements at the same time.
Zbog toga ne uzimajte Comtan i preparate željeza u isto vrijeme.
Therefore, do not take Comtess and iron supplements at the same time.
Zbog toga ne uzimajte Comtess i preparate željeza u isto vrijeme.
Therefore, do not take Entacapone Orion and iron supplements at the same time.
Zbog toga ne uzimajte Entacapone Orion i preparate željeza u isto vrijeme.
Therefore, do not take Entacapone Teva and iron supplements at the same time.
Zbog toga ne uzimajte Entakapon Teva i preparate željeza u isto vrijeme.
Therefore, do not take Levodopa/Carbidopa/Entacapone Orion and iron supplements at the same time.
Stoga ne uzimajte istodobno Levodopa/Carbidopa/Entacapone Orion i preparate željeza.
Therefore, do not take Pramipexole Teva if you are pregnant unless your doctor tells you to do so.
Stoga, ne uzimajte Pramipeksol Teva ako ste trudni, osim ako Vam Vaš liječnik tako kaže.
Therefore, do not wear contact lenses whilst using AZARGA.
Stoga nemojte nositi kontaktne leće dok koristite AZARGU.
Therefore, docetaxel must not be used during pregnancy unless clearly indicated.
Docetaksel se stoga ne smije primjenjivati tijekom trudnoće osim ako to nije striktno indicirano.
Therefore, dosage for adult and paediatric patients with mild, moderate or severe hepatic impairment should be started at the lower end of the recommended dosing range (4.5 ml/m2/day) and kept at the lowest dose necessary to control the patient’s ammonia levels.
Stoga, doziranje kod odraslih i pedijatrijskih bolesnika s blagim, umjerenim ili teškim oštećenjem jetre treba početi u najnižoj točki preporučenog raspona doziranja (4,5 ml/m2/dan) i održavati na najnižoj dozi potrebnoj za kontrolu razine amonijaka kod bolesnika.
Therefore, doses will be expressed in terms of both pramipexole base and pramipexole salt (in brackets).
Stoga će doze biti izražene i u obliku baze pramipeksola i u obliku soli pramipeksola (u zagradama).
Therefore, doses will be expressed in terms of both pramipexole base and pramipexole salt (in brackets).
Stoga će doze biti izražene i u obliku baze pramipeksola i u obliku soli pramipeksola (u zagradi).
Therefore, drinks containing plant extracts, including herbal teas, should not be taken together with Rasilez.
Stoga se napitci koji sadrže biljne ekstrakte, uključujući biljne čajeve, ne smiju uzimati zajedno s Rasilezom.
Therefore, due to the metformin active substance, Competact should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Budući da sadrži metformin kao djelatnu tvar, primjena lijeka Competact mora se prekinuti prije ili u vrijeme pretrage i može se nastaviti najranije 48 sati nakon pretrage i to tek nakon što se ponovnom procjenom funkcije bubrega ustanovi da je normalna (vidjeti dio 4.5).
Therefore, due to the metformin active substance, Eucreas should be discontinued prior to, or at the time of, the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Zbog toga što Eucreas sadrži metformin kao djelatnu tvar mora se prekinuti njegovo uzimanje prije ili za vrijeme pretrage i ne primjenjivati ga 48 sati nakon toga, i tada samo ako je učinjena ponovna procjena funkcije bubrega i utvrđeno da je ona normalna (vidjeti dio 4.5).
Therefore, due to the metformin active substance, Glubrava should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Budući da sadrži metformin kao djelatnu tvar, primjena lijeka Glubrava mora se prekinuti prije ili u vrijeme pretrage i može se nastaviti najranije 48 sati nakon pretrage i to tek nakon što se ponovnom procjenom funkcije bubrega ustanovi da je normalna (vidjeti dio 4.5).
Therefore, due to the metformin active substance, Icandra should be discontinued prior to, or at the time of, the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Zbog toga što Icandra sadrži metformin kao djelatnu tvar mora se prekinuti njegovo uzimanje prije ili za vrijeme pretrage i ne primjenjivati ga 48 sati nakon toga, i tada samo ako je učinjena ponovna procjena funkcije bubrega i utvrđeno da je ona normalna (vidjeti dio 4.5).
Therefore, due to the metformin active substance, Zomarist should be discontinued prior to, or at the time of, the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Zbog toga što Zomarist sadrži metformin kao djelatnu tvar mora se prekinuti njegovo uzimanje prije ili za vrijeme pretrage i ne primjenjivati ga 48 sati nakon toga, i tada samo ako je učinjena ponovna procjena funkcije bubrega i utvrđeno da je ona normalna (vidjeti dio 4.5).
Therefore, due to the risk of haemorrhage, notably with NSAIDs with elimination half-lives > 12 hours, close observation for signs of bleeding is recommended (see section 4.4).
Stoga se, zbog rizika od krvarenja, osobito uz NSAIL-e s poluvijekom eliminacije > 12 sati, preporučuje pažljiv nadzor znakova krvarenja (vidjeti dio 4.4).
Therefore, due to the studies reported, the spontaneous report and the strong likelihood of a class effect, section 4.4 and 5.2 of the Summary of Product Characteristics should be updated with this safety concern.
Stoga, zbog prijavljenih studija, spontanih prijava i velike vjerojatnosti učinka skupine, dio 4.4 i 5.2 Sažetka opisa svojstava lijeka potrebno je ažurirati ovim sigurnosnim pitanjem.
Therefore, Dukoral is not recommended to be used in children less than 2 years of age.
Zbog toga se ne preporučuje primjena cjepiva Dukoral u djece mlađe od 2 godine.
Therefore, dulaglutide does have a high degree of protection against DPP-4 inactivation (see section 5.1).
Stoga, dulaglutid doista pruža visok stupanj zaštite od inaktivacije DPP-4 (vidjeti dio 5.1).
Therefore, during the concomitant use of thiotepa and these medicinal products, patients should be carefully monitored clinically.
Zbog toga je potrebno pažljivo kliničko praćenje bolesnika tijekom istodobne uporabe tiotepe i ovih lijekova.
Therefore, during treatment with belatacept, vaccinations may be less effective although this has not been studied in clinical trials.
Stoga za vrijeme liječenja belataceptom cjepiva mogu biti manje učinkovita, iako se to nije ispitalo u kliničkim ispitivanjima.
Therefore, during treatment with belatacept, vaccinations may be less effective although this has not been studied in clinical trials.
Stoga, za vrijeme liječenja belataceptom, cijepljenja mogu biti manje učinkovita, iako se to nije ispitivalo u kliničkim ispitivanjima.
Therefore, each vial contains an excess amount of solvent and PegIntron powder to ensure delivery of the labelled dose in 0.5 ml of PegIntron, solution for injection.
Zato svaka bočica sadrži nešto veću količinu otapala i PegIntron praška kako bi se osigurala primjena deklarirane doze u 0,5 ml PegIntron otopine za injekciju.